Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 3Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Persistent Infection 1Neoplasm Metastasis 1Melanoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Condylomata Acuminata 1Colonic Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Vaccines × 1 year × Clear all
NCT06175221 2025-09-15

Autologous TLPO Vaccine Basket

Elios Therapeutics, LLC

Phase 2 Terminated
63 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡